Miller-Fisher syndrome (MFS) is a rare variant of Guillain-Barré syndrome characterized by a classic triad of ophthalmoplegia, ataxia, and areflexia. This acute peripheral neuropathy has a generally good natural prognosis and is usually triggered by preceding infections and occasionally post-vaccination events. Anti-ganglioside antibodies (particularly anti-GQ1b) are a significant diagnostic marker found in approximately 85% of patients with MFS. However, clinical severity for double antibody positivity is not well-defined in the literature. Intravenous immunoglobulin (IVIG) is used as a first-line treatment due to its immunomodulatory effects.

A 61-year-old female initially presented flu-like symptoms, followed by the onset of an unsteady gait and diplopia. Subsequently, she developed progressively worsening difficulty with phonation, prompting her to seek care at the emergency department. Her medical history was notable only for hypertension. During the neurological examination, the patient exhibited altered mental status and slurred speech. Cranial nerve assessment revealed limited eye movement and a diminished palatal reflex. Muscle tone and strength were normal, with a global muscle strength score of 5/5. Deep tendon reflexes were absent, and the patient was unable to walk. During her hospitalization, IVIG therapy was initiated. However, despite treatment, the patient experienced further deterioration, with worsening respiratory muscle weakness, necessitating intubation and intensive care management. The brain MRI and CSF were normal. Anti-GQ1b and Anti-GT1a Antibodies were found in the antibody panel. She was escalated to plasmapheresis, which finally showed clinical improvement. 

This case suggests the complexity of MFS with dual antibody positivity. The patient's clinical deterioration despite initial IVIG treatment highlights the importance of alternative therapies beyond first-line options. If available, antibody testing can guide early treatment decisions and potentially improve outcomes in these patients.